Rhonda Szczesniak1, Lidija Turkovic2, Eleni-Rosalina Andrinopoulou3, Harm A W M Tiddens4. 1. Division of Biostatistics & Epidemiology and Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. 2. Telethon Kids Institute, West Perth, Australia. 3. Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands. 4. Department of Pediatric Pulmonology and Allergology, The Netherlands; Department of Radiology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. Electronic address: h.tiddens@erasmusmc.nl.
Abstract
BACKGROUND: The dawn of precision medicine and CFTR modulators require more detailed assessment of lung structure in cystic fibrosis (CF) clinical studies. Various imaging markers have emerged and are measurable, but clarity is needed to identify what markers should count for clinical studies. High-resolution chest computed tomography (CT) scoring has yielded sensitive markers for the study of CF disease progression. Once completed, CT scores from ongoing randomized controlled trials can be used to examine relationships between imaging endpoints and therapeutic effectiveness. Similarly, Magnetic Resonance Imaging (MRI) is in development to generate structural as well as functional markers. RESULTS: The aim of this review is to characterize the role of currently available CT and MRI markers in clinical studies, and to discuss study design, data processing and statistical challenges unique to these endpoints in CF studies. Suggestions to overcome these challenges in CF studies are included. CONCLUSIONS: To maximize the potential of CT and MRI markers in clinical studies and advance treatment of CF disease progression, efforts should be made to conduct longitudinal randomized controlled trials including these modalities, develop data repositories, promote standardization and conduct reproducible research.
BACKGROUND: The dawn of precision medicine and CFTR modulators require more detailed assessment of lung structure in cystic fibrosis (CF) clinical studies. Various imaging markers have emerged and are measurable, but clarity is needed to identify what markers should count for clinical studies. High-resolution chest computed tomography (CT) scoring has yielded sensitive markers for the study of CF disease progression. Once completed, CT scores from ongoing randomized controlled trials can be used to examine relationships between imaging endpoints and therapeutic effectiveness. Similarly, Magnetic Resonance Imaging (MRI) is in development to generate structural as well as functional markers. RESULTS: The aim of this review is to characterize the role of currently available CT and MRI markers in clinical studies, and to discuss study design, data processing and statistical challenges unique to these endpoints in CF studies. Suggestions to overcome these challenges in CF studies are included. CONCLUSIONS: To maximize the potential of CT and MRI markers in clinical studies and advance treatment of CF disease progression, efforts should be made to conduct longitudinal randomized controlled trials including these modalities, develop data repositories, promote standardization and conduct reproducible research.
Authors: Claire E Wainwright; Suzanna Vidmar; David S Armstrong; Catherine A Byrnes; John B Carlin; Joyce Cheney; Peter J Cooper; Keith Grimwood; Marj Moodie; Colin F Robertson; Harm A Tiddens Journal: JAMA Date: 2011-07-13 Impact factor: 56.272
Authors: Mark O Wielpütz; Michael Puderbach; Annette Kopp-Schneider; Mirjam Stahl; Eva Fritzsching; Olaf Sommerburg; Sebastian Ley; Migle Sumkauskaite; Jürgen Biederer; Hans-Ulrich Kauczor; Monika Eichinger; Marcus A Mall Journal: Am J Respir Crit Care Med Date: 2014-04-15 Impact factor: 21.405
Authors: Lauren S Mott; Karla G Graniel; Judy Park; Nicholas H de Klerk; Peter D Sly; Conor P Murray; Harm A W M Tiddens; Stephen M Stick Journal: Chest Date: 2013-10 Impact factor: 9.410
Authors: Wieying Kuo; Mariette P C Kemner-van de Corput; Adria Perez-Rovira; Marleen de Bruijne; Isabelle Fajac; Harm A W M Tiddens; Marcel van Straten Journal: Eur Respir J Date: 2016-04-13 Impact factor: 16.671
Authors: Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes Journal: Am J Respir Crit Care Med Date: 2018-12-15 Impact factor: 21.405
Authors: Jason C Woods; Jim M Wild; Mark O Wielpütz; John P Clancy; Hiroto Hatabu; Hans-Ulrich Kauczor; Edwin J R van Beek; Talissa A Altes Journal: J Magn Reson Imaging Date: 2019-12-17 Impact factor: 4.813
Authors: Jennifer J Meerburg; Ieneke J C Hartmann; Sigune Goldacker; Ulrich Baumann; Annette Uhlmann; Eleni-Rosalina Andrinopoulou; Mariette P C Kemner V/D Corput; Klaus Warnatz; Harm A W M Tiddens Journal: Front Immunol Date: 2020-10-30 Impact factor: 7.561
Authors: Harm A W M Tiddens; Eleni-Rosalina Andrinopoulou; Joe McIntosh; J Stuart Elborn; Eitan Kerem; Nynke Bouma; Jochem Bosch; Mariette Kemner-van de Corput Journal: PLoS One Date: 2020-11-03 Impact factor: 3.240
Authors: Dimitrios Moutafidis; Maria Gavra; Sotirios Golfinopoulos; Antonios Kattamis; George Chrousos; Christina Kanaka-Gantenbein; Athanasios G Kaditis Journal: Children (Basel) Date: 2021-12-10
Authors: Eline Lauwers; Annemiek Snoeckx; Kris Ides; Kim Van Hoorenbeeck; Maarten Lanclus; Wilfried De Backer; Jan De Backer; Stijn Verhulst Journal: BMC Pulm Med Date: 2021-08-04 Impact factor: 3.317